

From the maker of RECOMBITEK[®],
PUREVAX[®], and IMRAB[®]




RECOMBITEK[®]
oral bordetella

**Rapid protection against an
important respiratory pathogen¹**

A fast, simple experience for everyone involved

**Dogs take enough risks on their own.
Reduce their risk the easy way.**



EFFECTIVE, SAFE PROTECTION MADE EASY

Convenient, needle-free delivery

- Oral administration offers low-stress vaccination
- No unpleasant sneeze-backs or wrestling with patients during intranasal delivery
- An easy experience for everyone in the room, including staff, dogs, and dog owners

Published efficacy data

- In a randomized, placebo-controlled study, vaccination with RECOMBITEK Oral Bordetella provided equivalent protection to an intranasal Bordetella vaccine in preventing disease due to *B. bronchiseptica* when compared to placebo^{1*}
- Dogs vaccinated with RECOMBITEK Oral Bordetella and an intranasal Bordetella vaccine had significantly lower incidence of disease ($P < 0.0001$) with 100% preventable fraction following a challenge with virulent *B. bronchiseptica* 7 days after vaccination¹
- This is the first published study that assessed efficacy of an oral *B. bronchiseptica* vaccine 7 days after administration¹
 - Prior studies have assessed efficacy at 3 or 4 weeks after administration^{2,3}

*Active disease was defined as spontaneous coughing on 2 or more consecutive days. The placebo contained the same inert ingredients as the test vaccine with no antigen.

Demonstrated safety


- Needle-free administration prevents risk of accidental subcutaneous injection
- No risk of reversion to virulence
- Can be given to puppies as young as 8 weeks of age to induce local (mucosal) and systemic immunity

“Excellent device. Easy to use, draws liquid cleanly, and delivers it very well with one squeeze.”

— F. Capella, Veterinarian

What do we know about mucosal vaccines?

- Well-documented efficacy¹⁻⁵
- No need for a booster 2-4 weeks after initial vaccination
- Optimal promotion of IgA, the antibody primarily associated with mucosal immunity^{3,5}



Flip-top cap designed for easy vial opening



Protection in 4 simple steps


- Ergonomically designed oral pipette for comfortable administration
- Pre-filled with diluent—no need to shake or swirl when reconstituting
- Needle-free reconstitution and administration reduces potential risk of injury to staff

1.




Open the vial by pushing the plastic cap up and over until the aluminum begins to break, then twist off the aluminum seal and remove the stopper

2.




Twist open diluent-filled pipette tip

3.



Expel the contents of the pipette into the vaccine vial. Draw rehydrated vaccine back into the pipette

4.



Administer in the patient's buccal cavity

This vaccine is brought to you by the maker of a full line of vaccine products, including RECOMBITEK®, PUREVAX®, and IMRAB®



Canine Guarantee

Backed by a trusted name in veterinary vaccines. We will cover reasonable diagnostic and treatment costs associated with Canine Infectious Respiratory Disease Complex caused by *Bordetella bronchiseptica* up to \$5,000 for a pet properly vaccinated with a Merial *B. bronchiseptica* vaccine as long as exposure has not occurred within 72 hours or more than 1 year following vaccination. Cases involving 6 or more dogs will be handled on a case-by-case basis.

For full details, ask your Representative about our Satisfaction Guarantee on RECOMBITEK or call our Veterinary Technical Solutions team at 1-888-637-4251 opt 1.

B. bronchiseptica: Easily transmitted through dog-to-dog contact, freshly contaminated fomites, and aerosol transmission⁴

Who's at risk?

- Socializers: dogs that live in densely populated areas, visit pet stores with their owners, or visit groomers
- Dogs that are boarded
- Dogs that interact with neighborhood dogs or travel with their owners to hotels or restaurants—places that may be frequented by other at-risk dogs
- In fact, dogs may even be exposed at animal hospitals

“Dogs all loved the liquid.
None were opposed.”

— B. Bryant, *Veterinarian*

References: 1. Scott-Garrard, MM., Chiang, Y., David, F. Comparative onset of immunity of oral and intranasal vaccines against challenge with *Bordetella bronchiseptica*. *Veterinary Record Open*. 2018;5:e000285. 2. Ellis JA, Gow SP, Waldner CL et al. Comparative efficacy of intranasal and oral vaccines against *Bordetella bronchiseptica* in dogs. *The Veterinary Journal*. 2016. 212:71-77. 3. Larson LJ, Thiel BE, Sharp P, Schultz RD. A comparative study of protective immunity provided by oral, intranasal and parenteral canine *Bordetella bronchiseptica* vaccines. *Intern J Appl Res Vet Med*. 2013;11(3):153-160. 4. Ford RB. Canine infectious respiratory disease. In: Greene CE, ed. *Infectious Diseases of the Dog and Cat*. 4th ed. St Louis, MO: Elsevier Saunders; 2012:55-67. 5. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. *Nat Rev Immunol*. 2006;6(2):148-158.

To learn more about RECOMBITEK vaccines and how they can benefit your patients, contact your Sales Representative or your Distributor Representative, call Customer Care at 1-888-637-4251 or visit MERALconnect.com

Ask your Representative about our Satisfaction Guarantee on RECOMBITEK.

Merial is now part of Boehringer Ingelheim.

RECOMBITEK®, PUREVAX®, and IMRAB® are registered trademarks of Merial and MERALconnect.com™ is a service mark of Merial. ©2018 Merial, Inc., Duluth, GA. All rights reserved. PET-0606-REC0718

